{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:13:28Z","timestamp":1793650408484,"version":"4.5.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Michael J. Fox Foundation - SYN TAP 2013"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Accumulation of alpha-synuclein (ASYN) in neurons and other CNS cell types may contribute to the underlying pathology of synucleinopathies including Parkinson\u2019s disease (PD), dementia with Lewy bodies (DLB) and Multiple Systems Atrophy (MSA). In support of this hypothesis for PD, ASYN immunopositive aggregates are a prominent pathological feature of PD, and mutations and gene multiplications of human wild type (WT) ASYN cause rare familial autosomal-dominant forms of PD. Targeted therapeutics that reduce the accumulation of ASYN could prevent or slow the neurodegenerative processes in PD and other synucleinopathies. NPT200-11 is a novel small molecule inhibitor of ASYN misfolding and aggregation. The effects of NPT200-11 on ASYN neuropathology were evaluated in animal models over expressing human alpha synuclein. Longitudinal studies using retinal imaging in mice expressing a hASYN::GFP fusion protein revealed that 2 months of once daily administration of NPT200-11 (5\u2009mg\/kg IP) resulted in a time-dependent and progressive reduction in retinal ASYN pathology. The effects of NPT200-11 on ASYN pathology in cerebral cortex and on other disease-relevant endpoints was evaluated in the Line 61 transgenic mouse model overexpressing human wild type ASYN. Results from these studies demonstrated that NPT200-11 reduced alpha-synuclein pathology in cortex, reduced associated neuroinflammation (astrogliosis), normalized striatal levels of the dopamine transporter (DAT) and improved motor function. To gain insight into the relationship between dose, exposure, and therapeutic benefit pharmacokinetic studies were also conducted in mice. These studies demonstrated that NPT200-11 is orally bioavailable and brain penetrating and established target plasma and brain exposures for future studies of potential therapeutic benefit.<\/jats:p>","DOI":"10.1038\/s41598-018-34490-9","type":"journal-article","created":{"date-parts":[[2018,10,26]],"date-time":"2018-10-26T06:02:52Z","timestamp":1540533772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":158,"title":["The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson\u2019s disease"],"prefix":"10.1038","volume":"8","author":[{"given":"Diana L.","family":"Price","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya A.","family":"Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Wrasidlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Rockenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliezer","family":"Masliah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Bonhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,1]]},"reference":[{"key":"34490_CR1","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/35081564","volume":"2","author":"M Goedert","year":"2001","unstructured":"Goedert, M. Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2, 492\u2013501 (2001).","journal-title":"Nat. Rev. Neurosci."},{"key":"34490_CR2","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1126\/science.1090278","volume":"302","author":"B Singleton","year":"2003","unstructured":"Singleton, B. et al. Alpha-Synuclein locus triplication causes Parkinson\u2019s disease. Science 302, 841 (2003).","journal-title":"Science"},{"key":"34490_CR3","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/ana.10795","volume":"55","author":"J Zarranz","year":"2004","unstructured":"Zarranz, J. et al. The new mutation E46K of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164\u2013173 (2004).","journal-title":"Ann. Neurol."},{"key":"34490_CR4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/j.1749-6632.2003.tb07475.x","volume":"991","author":"M Hashimoto","year":"2003","unstructured":"Hashimoto, M., Rockenstein, E. & Masliah, E. Transgenic models of alpha-synuclein pathology: past, present, and future. Ann. N. Y. Acad. Sci. 991, 171\u2013188 (2003).","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"Pt 12","key":"34490_CR5","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1093\/brain\/aww238","volume":"139","author":"W Wrasidlo","year":"2016","unstructured":"Wrasidlo, W. et al. A de novo compound targeting \u03b1-synuclein improves deficits in models of Parkinson\u2019s disease. Brain 139(Pt 12), 3217\u20133236 (2016).","journal-title":"Brain"},{"key":"34490_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/srep29523","volume":"6","author":"DL Price","year":"2016","unstructured":"Price, D. L. et al. Longitudinal live imaging of retinal \u03b1-synuclein::GFP deposits in a transgenic mouse model of Parkinson\u2019s Disease\/Dementia with Lewy Bodies. Sci. Rep. 6, 29523 (2016).","journal-title":"Sci. Rep."},{"key":"34490_CR7","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/jnr.20446","volume":"80","author":"E Rockenstein","year":"2005","unstructured":"Rockenstein, E. et al. Lysosomal pathology associated with alpha-synuclein accumulation in transgenic models using an eGFP fusion protein. J. Neurosci. Res. 80, 247\u2013259 (2005).","journal-title":"J. Neurosci. Res."},{"key":"34490_CR8","doi-asserted-by":"publisher","first-page":"e10589","DOI":"10.1371\/journal.pone.0010589","volume":"5","author":"VK Unni","year":"2010","unstructured":"Unni, V. K. et al. In vivo imaging of alpha-synuclein in mouse cortex demonstrates stable expression and differential subcellular compartment mobility. PLoS One 5, e10589 (2010).","journal-title":"PLoS One"},{"key":"34490_CR9","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1523\/JNEUROSCI.2581-13.2014","volume":"34","author":"KJ Spinelli","year":"2014","unstructured":"Spinelli, K. J. et al. Presynaptic alpha-synuclein aggregation in a mouse model of Parkinson\u2019s disease. J. Neurosci. 34, 2037\u20132050 (2014).","journal-title":"J. Neurosci."},{"issue":"5","key":"34490_CR10","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/jnr.10231","volume":"68","author":"E Rockenstein","year":"2002","unstructured":"Rockenstein, E. et al. Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J. Neurosci. Res. 68(5), 568\u201378 (2002).","journal-title":"J. Neurosci. Res."},{"issue":"2","key":"34490_CR11","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s13311-012-0104-2","volume":"9","author":"MF Chesselet","year":"2012","unstructured":"Chesselet, M. F. et al. A progressive mouse model of Parkinson\u2019s disease: the Thy1-aSYN (\u201cLine 61\u201d) mice. Neurotherapeutics 9(2), 297\u2013314 (2012).","journal-title":"Neurotherapeutics"},{"issue":"3","key":"34490_CR12","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.ajpath.2012.11.018","volume":"182","author":"D Games","year":"2013","unstructured":"Games, D. et al. Axonopathy in an \u03b1-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated \u03b1-synuclein. Am. J. Pathol. 182(3), 940\u201353 (2013).","journal-title":"Am. J. Pathol."},{"issue":"5456","key":"34490_CR13","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1126\/science.287.5456.1265","volume":"287","author":"E Masliah","year":"2000","unstructured":"Masliah, E. et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287(5456), 1265\u20139 (2000).","journal-title":"Science"},{"issue":"7","key":"34490_CR14","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1002\/jnr.22611","volume":"89","author":"HA Lam","year":"2011","unstructured":"Lam, H. A. et al. Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human \u03b1-synuclein. J. Neurosci. Res. 89(7), 1091\u2013102 (2011).","journal-title":"J. Neurosci. Res."},{"key":"34490_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-018-0276-2","volume":"13","author":"C Kim","year":"2018","unstructured":"Kim, C. et al. Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating \u03b1-synuclein transmission and neuroinflammation. Mol. Neurodegeneration 13, 43 (2018).","journal-title":"Mol. Neurodegeneration"},{"issue":"1","key":"34490_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12868-017-0341-8","volume":"18","author":"R Rabl","year":"2017","unstructured":"Rabl, R. et al. Early start of progressive motor deficits in Line 61 \u03b1-synuclein transgenic mice. BMC Neurosci. 18(1), 22 (2017).","journal-title":"BMC Neurosci."},{"issue":"42","key":"34490_CR17","doi-asserted-by":"publisher","first-page":"9434","DOI":"10.1523\/JNEUROSCI.3080-04.2004","volume":"24","author":"SM Fleming","year":"2004","unstructured":"Fleming, S. M. et al. Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J. Neurosci. 24(42), 9434\u201340 (2004).","journal-title":"J. Neurosci."},{"issue":"12","key":"34490_CR18","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1074\/mcp.R113.032730","volume":"12","author":"AW Schmid","year":"2013","unstructured":"Schmid, A. W., Fauvet, B., Moniatte, M. & Lashuel, H. A. Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies. Mol. Cell. Proteomics 12(12), 3543\u201358 (2013).","journal-title":"Mol. Cell. Proteomics"},{"key":"34490_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/srep41051","volume":"7","author":"SJ Roeters","year":"2017","unstructured":"Roeters, S. J. et al. Evidence for Intramolecular Antiparallel Beta-Sheet Structure in Alpha-Synuclein Fibrils from a Combination of Two-Dimensional Infrared Spectroscopy and Atomic Force Microscopy. Sci. Rep. 7, 41051 (2017).","journal-title":"Sci. Rep."},{"key":"34490_CR20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrn3406","volume":"14","author":"HA Lashuel","year":"2013","unstructured":"Lashuel, H. A., Overk, C. R., Oueslati, A. & Masliah, E. The many faces of alpha-synuclein: from structure and toxicity to therapeutic target. Nature Rev. Neurosci. 14, 38\u201348 (2013).","journal-title":"Nature Rev. Neurosci."},{"key":"34490_CR21","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1146\/annurev.neuro.26.010302.081142","volume":"26","author":"B Caughey","year":"2003","unstructured":"Caughey, B. & Lansbury, P. T. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annual Rev. Neurosci. 26, 267\u2013298 (2003).","journal-title":"Annual Rev. Neurosci."},{"key":"34490_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/mds.25373","volume":"28","author":"CW Olanow","year":"2013","unstructured":"Olanow, C. W. & Brundin, P. Parkinson\u2019s disease and alpha synuclein: is Parkinson\u2019s disease a prion-like disorder? Movement Disorders 28, 31\u201340 (2013).","journal-title":"Movement Disorders"},{"issue":"6","key":"34490_CR23","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nm.2165","volume":"16","author":"JA Obeso","year":"2010","unstructured":"Obeso, J. A. et al. Missing pieces in the Parkinson\u2019s disease puzzle. Nat. Med. 16(6), 653\u201361 (2010).","journal-title":"Nat. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-34490-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-34490-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-34490-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T06:11:40Z","timestamp":1671603100000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-34490-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,1]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["34490"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-34490-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,1]]},"assertion":[{"value":"27 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"16165"}}